BMS's Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia
Shots:
- The approval is based on the P-lll BELIEVE study assessing Reblozyl (luspatercept) + BSC vs PBO + BSC in adult patients with anemia associated with beta-thalassemia requiring regular RBC transfusions
- Result: ≥33% reduction in RBC transfusion with a reduction of ≥2units from 13-24wks. (21.4% vs. 4.5%)- results were published in NEJM
- Reblozyl regulate late-stage RBC maturation to potentially reduce the number of regular RBC transfusions and is the first and only erythroid maturation agent approved in Canada
Ref: BMS | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com